Spruce Biosciences, Inc. Increase (Decrease) in Accounts Payable
Spruce Biosciences, Inc. (SPRB) reported Increase (Decrease) in Accounts Payable of $266.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-12
- Spruce Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$1.43M.
- Spruce Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $1.70M, a 191.10% increase year-over-year.
- Spruce Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$443.00K.
- Spruce Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $579.00K, a 48.16% decline year-over-year.
- Spruce Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$352.00K.
- Spruce Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$2.04M, a 206.87% decline from fiscal 2023.
- Spruce Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2023 was $1.91M.
- Spruce Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2022 was -$1.40M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $266.00K 10-Q · filed 2026-08-12 | -$177.00K derived: sum of 3 quarters · filed 2026-08-12 | $402.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.70M 10-Q · filed 2026-05-13 | $1.26M derived: sum of 2 quarters · filed 2026-05-13 | $1.84M derived: sum of 3 quarters · filed 2026-05-13 | $764.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$443.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $136.00K derived: sum of 2 quarters · filed 2026-03-09 | -$936.00K derived: sum of 3 quarters · filed 2026-08-12 | -$352.00K 10-K · filed 2026-03-09 |
| 2025-09-30 | $579.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$493.00K derived: sum of 2 quarters · filed 2026-08-12 | $91.00K 10-Q · filed 2025-11-10 | -$413.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$488.00K 10-Q · filed 2026-08-12 | -$992.00K derived: sum of 3 quarters · filed 2026-08-12 | $125.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $584.00K 10-Q · filed 2026-05-13 | $80.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.20M derived: sum of 3 quarters · filed 2026-05-13 | -$12.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$504.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $613.00K derived: sum of 2 quarters · filed 2026-03-09 | -$596.00K derived: sum of 3 quarters · filed 2026-03-09 | -$2.04M 10-K · filed 2026-03-09 |
| 2024-09-30 | $1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$92.00K derived: sum of 2 quarters · filed 2025-11-10 | -$1.53M 10-Q · filed 2025-11-10 | -$1.35M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$2.65M 10-Q · filed 2025-08-14 | -$2.47M derived: sum of 3 quarters · filed 2025-08-14 | -$263.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$1.44M 10-Q · filed 2025-05-06 | -$1.26M derived: sum of 2 quarters · filed 2025-05-06 | $946.00K derived: sum of 3 quarters · filed 2025-05-06 | -$1.56M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $180.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $2.39M derived: sum of 2 quarters · filed 2025-04-15 | -$116.00K derived: sum of 3 quarters · filed 2025-04-15 | $1.91M 10-K · filed 2025-04-15 |
| 2023-09-30 | $2.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$296.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.73M 10-Q · filed 2024-11-12 | $971.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$481.00K 10-Q · filed 2024-08-12 | -$1.24M derived: sum of 3 quarters · filed 2024-08-12 | -$500.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $2.02M 10-Q · filed 2024-05-13 | $1.27M derived: sum of 2 quarters · filed 2024-05-13 | $2.00M derived: sum of 3 quarters · filed 2024-05-13 | $2.34M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$755.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$19.00K derived: sum of 2 quarters · filed 2024-03-18 | $317.00K derived: sum of 3 quarters · filed 2024-03-18 | -$1.40M 10-K · filed 2024-03-18 |
| 2022-09-30 | $736.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $1.07M derived: sum of 2 quarters · filed 2023-11-13 | -$642.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $336.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$1.38M 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | -$1.71M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | -$805.00K 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |